

JOIN YOUR COLLEAGUES ...

at these and other fine institutions by committing to participate in the Hemovigilance portion of the US Biovigilance Network:

Aurora St. Luke's Medical Center | Baystate Medical Center | Beth Israel Deaconess Medical Center

Central Florida Regional Hospital | Children's Healthcare of Atlanta | Children's Hospital (Los Angeles)

Children's Hospital (Dallas) | Cleveland Clinic | Columbia University Hospital | Community Blood Center (Dayton)

Danbury Hospital | Dartmouth Hitchcock Medical Center | Emory Crawford Long Hospital | Emory University Hospital

Euclid Hospital | Fairview Hospital | Fairview Southdale Hospital | Froedtert & The Medical College of Wisconsin

Fletcher Allen Health Care | Genesis Medical Center | Grady Memorial Hospital | Hahnemann University Hospital

Hennepin County Medical Center | Henry Ford Hospital/Henry Ford Health System | Hillcrest Hospital

Hoxworth Blood Center | The Johns Hopkins Hospital and Health System | Lakewood Hospital | Lutheran Hospital

Maimonides Medical Center | Marymount Hospital | M. D. Anderson Cancer Center | Mayo Clinic (Scottsdale)

New York Presbyterian Hospital | NorthShore University Health System | Ochsner Health System Blood Bank

Puget Sound Blood Center | Shands Hospital at the University of Florida | South Pointe Hospital

St. Luke's Episcopal Hospital | St. Mary's Regional Blood Center | UCLA Health System

Underwood Memorial Hospital | University Hospital Case Medical Center | University of Texas Medical Branch

VA Connecticut Healthcare System | Yale-New Haven Hospital



Hemovigilance is launching in February 2010

Participate Now!

"The Hemovigilance Module enables us to improve patient safety in one of the largest and most active transfusion services in the U.S.—and regardless of facility size, a national system allows for a collective learning experience, providing the opportunity to improve health care across the country."

— Dr. Paul Ness
Director, Transfusion Medicine
The Johns Hopkins Hospital

For More Information:

AABB will continue to keep you updated with relevant information and instructions. Questions and expressions of interest can be directed to:

AABB
Attn: Biovigilance
8101 Glenbrook Road
Bethesda, MD 20814

Phone: 301.215.6588
Fax: 301.907.6895
Email: biovigilance@aabb.org
www.aabb.org/biovigilance



Advancing Transfusion and
Cellular Therapies Worldwide



Advancing Transfusion and
Cellular Therapies Worldwide

U.S. Biovigilance Network

Investing in patient safety and donor health

Hemovigilance Participation Checklist ✓

ENGAGE — Complete the *Intent to Participate Form*

PREPARE — Train staff on standardized protocol and definitions and ensure participation in NHSN

JOIN — Begin capturing data in the NHSN Hemovigilance Module

Visit AABB.org/Biovigilance for a detailed checklist and all relevant documents. Or call us at 301-215-6588 to help you through the process.

Benefits:

- Reporting and quality tools
- Benchmarking against other facilities
- Nationally consistent definitions for adverse reactions and incidents associated with transfusion
- Potential for cost savings through identification of inefficiencies
- Data is anonymously compiled on a national level for better trending and increased learning
- In-depth analysis by qualified experts for the purpose of recommending nationwide patient safety enhancements
- **No fees to participate**

Common Questions

How is the data protected?

There are several federally mandated requirements that will ensure data protection including CDC's Assurance of Confidentiality through the Public Health Services Act and the Health Insurance Portability and Accountability Act of 1996 (HIPAA).

Won't this increase our workload?

Since you are already investigating and collecting data on adverse events, adopting standardized definitions will allow your facility to take advantage of lessons learned from the national system. Data entry is fast and easy and can be done at your convenience at least once per month in the Hemovigilance Module of the National Healthcare Safety Network (NHSN). Managed by the Centers for Disease Control and Prevention (CDC), NHSN is a secure, web-based healthcare data collection system and is already used by over 2,600 hospitals nationwide.

The U.S. Biovigilance Network

is the first national collaboration between government and nongovernment agencies to track adverse reactions and incidents associated with blood collection and transfusion as well as tissue, organ, and cell therapy transplantation.

After a successful pilot phase in 2009, Hemovigilance is the first component to launch. Data entry can be done quickly and securely online using the Hemovigilance Module of CDC's National Healthcare Safety Network (NHSN).

For more information go online:
www.aabb.org/biovigilance

"The Hemovigilance Module is an efficient way for any hospital, large or small, to analyze comprehensive patient safety data on adverse events associated with transfusion while contributing to a national healthcare improvement system."

— *Ileana Lopez-Plaza, MD*
Division Head, Transfusion Medicine
Henry Ford Health System